Cancer and the Immune System: The History and Background of Immunotherapy - PubMed (original) (raw)
Review
Cancer and the Immune System: The History and Background of Immunotherapy
Maura Abbott et al. Semin Oncol Nurs. 2019 Oct.
Abstract
Objective: This article will outline the link between the immune system and cancer, and provide a historical timeline of immunotherapy developmental milestones.
Data sources: Published data and peer reviewed publications/manuscripts, and textbook chapters.
Conclusion: Science has provided a greater understanding of the interactions between cancer and the human immune system. As this knowledge has grown, there has been significant progress in the development of clinically effective cancer immunotherapies.
Implications for nursing practice: Nurses' knowledge of the different types of immunity and the interaction of cancer cells with the immune system provides foundational knowledge for understanding cancer immunotherapy. Familiarity with the history of cancer immunotherapy will allow nurses to better comprehend why immunotherapy is now a pillar of cancer treatment that continues to develop. This knowledge will translate to better understanding and provision of care for patients receiving immunotherapy for the treatment of cancer.
Keywords: Adaptive immunity; Cancer immunotherapy; History; Immunotherapy history; Innate immunity.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
- Considerations for successful cancer immunotherapy in aged hosts.
Hurez V, Padrón Á, Svatek RS, Curiel TJ. Hurez V, et al. Exp Gerontol. 2018 Jul 1;107:27-36. doi: 10.1016/j.exger.2017.10.002. Epub 2017 Oct 4. Exp Gerontol. 2018. PMID: 28987644 Review. - Immunotherapy in Pediatric Oncology: An Overview of Therapy Types and Nursing Implications.
Warren CB. Warren CB. Clin J Oncol Nurs. 2018 Dec 1;22(6):649-655. doi: 10.1188/18.CJON.649-655. Clin J Oncol Nurs. 2018. PMID: 30452014 Review. - The Future of Immunotherapy in the Treatment of Cancer.
Kottschade LA. Kottschade LA. Semin Oncol Nurs. 2019 Oct;35(5):150934. doi: 10.1016/j.soncn.2019.08.013. Epub 2019 Aug 30. Semin Oncol Nurs. 2019. PMID: 31477413 Review. - In this issue: Role of immune cells, immune modulating factors and immunotoxins in cancer immunotherapy.
Kumar H, Bot A. Kumar H, et al. Int Rev Immunol. 2017 Jul 4;36(4):205-206. doi: 10.1080/08830185.2017.1326784. Epub 2017 May 24. Int Rev Immunol. 2017. PMID: 28537793 No abstract available. - Patient education resources related to biotherapy and the immune system.
Straw LJ, Conrad KJ. Straw LJ, et al. Oncol Nurs Forum. 1994 Aug;21(7):1223-8. Oncol Nurs Forum. 1994. PMID: 7971432
Cited by
- GUCA2A dysregulation as a promising biomarker for accurate diagnosis and prognosis of colorectal cancer.
Jalali P, Aliyari S, Etesami M, Saeedi Niasar M, Taher S, Kavousi K, Nazemalhosseini Mojarad E, Salehi Z. Jalali P, et al. Clin Exp Med. 2024 Nov 1;24(1):251. doi: 10.1007/s10238-024-01512-y. Clin Exp Med. 2024. PMID: 39485546 Free PMC article. - Tumour Immunotherapy and Applications of Immunological Products: A Review of Literature.
Oli AN, Adejumo SA, Rowaiye AB, Ogidigo JO, Hampton-Marcell J, Ibeanu GC. Oli AN, et al. J Immunol Res. 2024 Oct 24;2024:8481761. doi: 10.1155/2024/8481761. eCollection 2024. J Immunol Res. 2024. PMID: 39483536 Free PMC article. Review. - Bidirectional regulation of the cGAS-STING pathway in the immunosuppressive tumor microenvironment and its association with immunotherapy.
Zhang Y, Wang Y, Mu P, Zhu X, Dong Y. Zhang Y, et al. Front Immunol. 2024 Oct 11;15:1470468. doi: 10.3389/fimmu.2024.1470468. eCollection 2024. Front Immunol. 2024. PMID: 39464890 Free PMC article. Review. - Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges.
Rizzo A, Brunetti O, Brandi G. Rizzo A, et al. Int J Mol Sci. 2024 Oct 15;25(20):11091. doi: 10.3390/ijms252011091. Int J Mol Sci. 2024. PMID: 39456872 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials